Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qihan Raises $20 Million for Gene Editing to Enable Xenotransplants

publication date: Jul 25, 2019

Qihan Biotech, a Hangzhou startup, raised $20 million in a B round to advance its use of CRISPR Cas-9 gene editing to allow xenotransplantation, the use of animal organs as transplants. The round was led by CMB International and Legend Star. Qihan's goal is to remedy the global shortage of human organs for transplants. The company was founded by the chief scientist of eGenesis, Luhan Yang, PhD, and Harvard professor George Church, PhD. eGenesis is also focused on the use of CRISPR Cas-9 gene editing to enable xenotransplantation. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China